A core network of genes maintaining pluripotency has been at least partially defined. How the genetic switch is flipped to differentiation is the subject of a new study that reveals some unexpected players.
The past decade has witnessed immense progress in our understanding of how embryonic stem (ES) cell pluripotency and self-renewal are controlled at the molecular level. Despite these advances, vanishingly little is known about the initial events that dissolve this ground state circuitry and allow differentiation to unfurl. In this issue of Cell, Betschinger et al. tackle this conundrum and identify a hitherto uncharacterized sentinel at the exit door to differentiation (Betschinger et al., 2013) .
Pluripotent mouse ES cells are easily maintained in medium supplemented with two small molecule inhibitors (2i culture). This formulation ensures uniform and robust expression of signature marker genes, e.g., Oct4, Sox2, and Nanog, resulting in so-called ''naive'' pluripotency (Wray et al., 2010) . Betschinger et al. exploited the simple 2i platform to perform a high-throughput siRNA screen for genes whose loss safeguards pluripotency in the face of differentiation conditions-specifically, 2i withdrawal. Their screen was successful, as several genes encoding components of the FGF/ MAPK-and Wnt/GSK3-signaling pathways-the targets of 2i inhibition-were recovered. It also yielded a few surprises.
Among the novel hits was the tumor suppressor Folliculin (Flcn). Flcn encodes an evolutionarily conserved cytoplasmic protein with no recognizable motifs and no previously described role in ES cell biology. FLCN was first identified as the gene mutated in Birt-Hogg-Dubé (BHD) syndrome, which is characterized by numerous benign hair follicle tumors, for which Flcn is named (Nickerson et al., 2002) . Flcn likely piqued the author's interest because loss-of-function studies in mouse previously showed that Flcn null embryos die soon after implantation with a disorganized epiblast (Hasumi et al., 2009) . One possible explanation for this phenotype is that epiblast cells fail to disengage the pluripotency program and are effectively stuck developmentally. This is supported by the author's observation that Flcn knockdown ES cells do not differentiate even when confronted with a potent trio of recombinant growth factors that normally induces robust mesendoderm differentiation. Flcn is therefore required for efficient exit from naive pluripotency (Figure 1 ).
Although not found in their siRNA screen, the authors also investigated two previously identified Flcn-interacting proteins, Fnip1 and -2 (Baba et al., 2006) . Biochemical experiments confirm the existence of Flcn-Fnip1 complexes in ES cells, and Fnip1/2 knockdown cells withstand differentiation conditions comparable to loss of Flcn. Fnip-Flcn1 provides an intriguing mechanistic link to the mTOR pathway. mTOR is a multifunctional kinase that serves as a nexus for diverse cellular inputs, from nutrient deprivation to growth factor and hormone signals (Laplante and Sabatini, 2012) . Fnip1 was previously shown to bind AMPK, which phosphorylates Flcn and Fnip1 and also Tsc2, a negative regulator of mTOR (Baba et al., 2006) . Tsc2 is among the top hits from the siRNA screen, indicating that increased mTOR signaling opposes exit from the ground state.
What are the downstream targets of Flcn? One clue emerged from studies of the bHLH transcription factor TFE3. In a BHD cancer cell line, TFE3 is constitutively nuclear (Hong et al., 2010) . In mouse ES cells, Tfe3 is distributed heterogeneously in both the nucleus and cytoplasm. Similar to BHD cells, knockdown of Flcn results in nuclear Tfe3. During differentiation, however, Tfe3 is restricted exclusively to the cytoplasm of wild-type ES cells (Figure 1 ) but remains mostly nuclear in differentiation-resistant clones depleted of Flcn, Fnip1/2, or Tsc2. Interestingly, a similar pattern of Tfe3 subcellular distribution was observed in vivo. In blastocyst-stage mouse embryos, Tfe3 is observed in the nucleus of pluripotent inner cell mass cells. Soon after implantation, Tfe3 protein is exclusively cytoplasmic in the epiblast epithelium-the seat of primed pluripotency just prior to gastrulation. The author's in vitro results predict that nuclear Tfe3 will persist in Flcn À/À embryos.
Tfe3 is firmly established as the key functional mediator of input from FlcnFnip1/2 and Tsc2/mTOR by epistasis studies demonstrating that knockdown of Tfe3 restores the ability of clones depleted of Flcn, Fnip1/2, or Tsc2 to differentiate. The authors further show that Tfe3 is indeed sufficient to block exit from naive pluripotency. An engineered form of Tfe3 that allows for inducible nuclear translocation permits normal differentiation when left cytoplasmic but, when forced into the nucleus, precludes differentiation.
These initial findings raise a number of interesting questions. First, how is restoration of FGF and Wnt signaling at the onset of differentiation relayed to Flcn, resulting in Tfe3 nuclear exclusion? Tsc2 is the likely sensor, given that it integrates inputs from both the FGF-and Wntsignaling pathways (Laplante and Sabatini, 2012) . It is, however, unknown whether Flcn is directly phosphorylated by mTOR, which would suggest a linear Tsc2/mTOR/Flcn pathway, or other kinases in ES cells, or even whether such phosphorylation is significant functionally. Second, is Tfe3 actively exported from the nucleus at the onset of differentiation, or, alternatively, is its nuclear import simply inhibited? In this regard, it will be interesting to determine the Tfe3 interactome, both when Tfe3 is forced to be predominantly nuclear, such as in Flcn-shRNA knockdown ES cells, and during differentiation, when Tfe3 is cytoplasmic. Similarly, Flcn itself is a mysterious protein, and identifying interacting partners alongside structure-function studies will further elaborate its role in driving exit from pluripotency. It remains possible that Flcn itself sequesters Tfe3 in the cytoplasm.
Astonishingly, cells with constitutively nuclear Tfe3 grow and remain pluripotent without 2i! This unprecedented finding emphasizes how powerfully Tfe3 impacts the transcriptional network underlying ES cell self-renewal and immediately invites questions about the identity of Tfe3 transcriptional targets. Chromatin immunoprecipitation-sequencing studies reveal $1,500 genes that are cobound by Tfe3, Oct4/Sox2/Nanog, and the Wnt/GSK3 signaling effector Tcf3. Among these co-occupied loci were well-established regulators of pluripotency, including the nuclear hormone receptor Essrb (Figure 1 ). Essrb is a crucial direct target of Wnt/GSK3 and Nanog in the maintenance of ES cell renewal (Festuccia et al., 2012; Martello et al., 2012) . Essrb knockdown was, however, only able to partially overcome the differentiation barrier erected by nuclear Tfe3, indicating that other key Tfe3 targets lurk among the author's gene lists. In fact, Tfe3 effectively trumps the ability of Essrb or Nanog to individually sustain ES cell self-renewal, as overexpression of either factor still requires tailored medium formulations (Festuccia et al., 2012; Martello et al., 2012; Ying et al., 2008) .
In sum, the groundbreaking results of Betschinger et al. lift Tfe3 out of relative obscurity and will likely grab the attention of diverse scientists, emboldening the pursuit of a deeper understanding of the Flcn-Tfe3 gatekeeper module with fervor equal to the study of the previously anointed ''core'' pluripotency factors. In medium supplemented with 2i (MEKi and GSK-3bi), the expression of the pluripotency gene Esrrb is directly regulated by Nanog. Tfe3 is found in both the cytoplasm and in the nucleus, where it binds Esrrb and supports expression of ground-state factors. When 2i is withdrawn, mouse ES cells exit the pluripotent ground state and begin commitment. Exit is accompanied by decreasing Esrrb expression, resulting from a decline in Nanog levels, inhibition by Tcf3, and nuclear exclusion of Tfe3. Flcn-Fnip1/2 and Tsc1/2 are necessary to restrict Tfe3 to the cytoplasm. Tsc1/2 keep mTOR activity low during ES cell exit from ground state. After exit, AMPK may positively regulate Flcn to constrain Tfe3 to the cytoplasm.
